QuantaMatrix
QuantaMatrix is a Seoul-based in-vitro diagnostics company that builds microfluidic and multiplex assay platforms to deliver rapid antimicrobial susceptibility testing and multi-marker disease screening for hospital clinical microbiology laboratories across 26 countries in Europe and the Middle East.
- Company typePublic
- Founded2010
- HeadquartersSeoul, South Korea
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What QuantaMatrix does
QuantaMatrix is a South Korea-headquartered in-vitro diagnostics company, founded in 2010 as a spin-off from Seoul National University's Biophotonics and Nano Engineering Lab, that develops rapid diagnostic platforms for infectious disease and disease screening applications. The company's technology stack is built on two proprietary platforms: a Microfluidic Agarose Channel (MAC) system combined with time-lapse microscopic imaging for phenotypic antimicrobial susceptibility testing, and a QuantaMatrix Multiplex Assay Platform (QMAP) using coded Microdisk microparticles for simultaneous multi-biomarker detection. Its commercial product portfolio centers on dRAST, which delivers MIC-based antimicrobial susceptibility results from positive blood cultures in as few as 4 hours versus 2-3 days for conventional methods; QDST for tuberculosis drug susceptibility testing in 7 days; QPLEX Alz plus for blood-based early Alzheimer's diagnosis; Quanti9 and QuantiGal for cardiovascular risk prediction; and uRAST, a next-generation system published in Nature in August 2024 that produces results within 13 hours directly from blood samples.
QuantaMatrix generates revenue through a hybrid model combining capital equipment sales of automated diagnostic instruments (dRAST, QDST, QMIA) with recurring consumables revenue from proprietary test kit panels, agarose, and broth. The company sells directly to hospital clinical microbiology laboratories through enterprise field sales and through a distribution network covering 26 countries across Europe and the Middle East, with named channel partners including Argenta (Poland), Neo-Science (UAE), and Limbach Group (Germany), plus inclusion in the UniHA French hospital purchasing consortium catalog. QuantaMatrix has been publicly listed on the Korean KOSDAQ exchange under ticker A317690 since December 2020, when it raised $40.2 million USD at its IPO, and most recently received a $2.85 million USD CARB-X grant in August 2025 to develop a neonatal sepsis diagnostic platform. The company maintains its headquarters in Seoul, a European subsidiary office in Villejuif, France, and an R&D presence at Seoul National University Hospital.
QuantaMatrix firmographics
Firmographics- Name
- QuantaMatrix
- Legal name
- QuantaMatrix Inc.
- Website
- https://quantamatrix.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- QuantaMatrix is a Seoul-based in-vitro diagnostics company that builds microfluidic and multiplex assay platforms to deliver rapid antimicrobial susceptibility testing and multi-marker disease screening for hospital clinical microbiology laboratories across 26 countries in Europe and the Middle East.
- Ownership category
- akta.pro rank
QuantaMatrix industry classification
Industry- Product category
- In-vitro Diagnostics (Clinical Microbiology)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
- akta.pro secondary industries
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where QuantaMatrix is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices4 records
Markets served
QuantaMatrix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Systems and Consumables: Sale of automated diagnostic instruments (dRAST, QDST, QMIA) along with proprietary test kits and consumables including panels, agarose, and broth. Revenue generated from capital equipment sales and recurring consumable revenue from test kit purchases.
- Diagnostic Testing Kits: Proprietary test kits for antimicrobial susceptibility testing (dRAST panels, QDST panels) and disease detection (QPLEX, Quanti9/QuantiGal). Consumables revenue from hospitals and laboratories performing tests.
Go-to-market motion3 records
Distribution channels6 records
Marketing channels8 records
QuantaMatrix product offering
Product offeringCore offering
QuantaMatrix develops and commercializes rapid in-vitro diagnostic systems for clinical microbiology, with flagship applications in bloodstream infection/sepsis antimicrobial susceptibility testing (dRAST), tuberculosis drug susceptibility testing (QDST), Alzheimer's disease screening (QPLEX Alz plus), and cardiovascular diagnostics (Quanti9 and QuantiGal). Its portfolio combines proprietary microfluidic agarose channel hardware, time-lapse imaging software, and multiplex immunoassays, sold as integrated instruments plus consumables to hospital laboratories and reference centers.
Product overview
QuantaMatrix is an in-vitro diagnostics company offering a portfolio of rapid diagnostic solutions built on its proprietary microfluidic and multi-marker technology platforms. The product portfolio centers on two core platforms — the MAC (Microfluidic Agarose Channel) technology for phenotypic antimicrobial susceptibility testing, and the QMAP (QuantaMatrix Multiplex Assay Platform) using coded Microdisk technology for multi-marker immunoassay detection. The lead product, dRAST (direct & Rapid Antimicrobial Susceptibility Test), provides MIC-based AST results directly from positive blood cultures in as little as 4 hours via microfluidic agarose channel and time-lapse microscopic imaging, with 2 panels (Gram-negative and Gram-positive) supporting CLSI and EUCAST guidelines. QDST delivers TB drug susceptibility results in 7 days using the same MAC technology with enhanced biosafety. The QMAP-based QPLEX Alz plus assay detects 4 Alzheimer's disease biomarkers from blood plasma via the automated QMIA system, and the ELISA-based Quanti9 & QuantiGal kits predict heart failure risk from cardiovascular biomarkers. The next-generation uRAST eliminates blood culture entirely, producing results in 13 hours with a 94.9% accuracy rate, and QMAP One-pot Assay targets neonatal sepsis with 6-hour turnaround from minimal blood volumes.
Differentiator
Problem solved
Functional benefit
Brands
- dRAST: Direct & Rapid Antimicrobial Susceptibility Testing system providing MIC-based phenotypic AST results in as low as 4 hours from positive blood cultures.
- QDST
- QMAP
- QMIA
- QMAP 2.0
- Quanti9
- QuantiGal
Products and services
- dRAST
Quantifiable outcome
- dRAST reduces AST turnaround from 64.5 hours (conventional) to 14.3 hours average; time to optimal treatment decreased by 14 hours (39.0 hrs vs 53.2 hrs)
- +5 more outcomes
Companies that use QuantaMatrix
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles1 record
QuantaMatrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature6 records
QuantaMatrix partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and flagship.
- Seoul National University HospitalcoreClinical validation partner for uRAST technology testing. Hospital conducted validation studies demonstrating uRAST reduced time from positive blood culture to optimal antimicrobial prescription by average of 13 hours compared to conventional methods. Published results in Nature journal.
- Argenta Sp. z o.o.corePolish distribution partner for dRAST sepsis solution. Partnered with QuantaMatrix to secure WOŚP sepsis tender, supplying 20 dRAST units to Polish hospitals and healthcare institutions. Argenta provides sales, clinical education, and after-sales service support in Poland.
- UniHAflagshipUnion of Hospitals for Purchasing - French hospital purchasing consortium. dRAST has been integrated and validated into UniHA's product catalog, enabling simplified procurement of the diagnostic system for member hospitals across France.
- Neo-SciencecoreDistribution partnership for UAE market covering the Middle East region. Neo-Science serves as the authorized distributor for QuantaMatrix products in the United Arab Emirates, expanding the company's presence in the Middle East and Africa region.
- Limbach GroupcoreGerman laboratory group that adopted QuantaMatrix's dRAST in routine clinical use. Represents implementation of dRAST technology in European healthcare system, demonstrating adoption by major laboratory network.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
QuantaMatrix competitors and assessment
Company assessmentDirect peers
- bioM\u00e9rieux: Global leader in clinical microbiology diagnostics with the VITEK 2 AST platform, which competes head-to-head with QuantaMatrix dRAST/uRAST in hospital laboratories. Direct overlap in phenotypic antimicrobial susceptibility testing and sepsis workflows.
- Accelerate Diagnostics: Commercializes the Accelerate Pheno system, a rapid phenotypic AST platform delivering results in hours from positive blood cultures. Most direct competing technology stack and customer segment to QuantaMatrix dRAST.
Broad incumbents
- Becton Dickinson (BD): Major incumbent in clinical microbiology and hospital-acquired infection diagnostics through BD MAX and BD Phoenix AST systems. Overlaps with QuantaMatrix on hospital microbiology customers and antimicrobial stewardship positioning.
- Bruker Corporation: Operates the MALDI Biotyper for microbial ID and is expanding into AST via the MBT-ASTRA workflow. Competes on the same hospital bloodstream infection pathway as QuantaMatrix dRAST/uRAST, often as the upstream ID step.
- Beckman Coulter (Danaher): Supplies the MicroScan AST platform used widely in hospital microbiology labs. Overlaps with QuantaMatrix's hospital clinical microbiology customer base and antimicrobial susceptibility reporting workflows.
- Cepheid (Danaher): GeneXpert system is the dominant rapid molecular TB testing platform with integrated DST. Competes with QuantaMatrix QDST for TB drug susceptibility throughput in reference laboratories.
- Roche Diagnostics: Broad IVD incumbent offering cobas blood culture and AST solutions plus Alzheimer's CSF biomarker assays (Elecsys). Competes with QuantaMatrix in the same hospital lab purchasing decisions across multiple indications.
Emerging players
- T2 Biosystems: Develops T2 Magnetic Resonance-based direct-from-blood pathogen detection for bloodstream infections. Adjacent emerging technology targeting the same sepsis use case as uRAST but using molecular rather than phenotypic methodology.
- Qvella Corporation: Developer of the FAST ID/AST system for rapid direct-from-sample bloodstream infection testing. Early-stage competitor pursuing a similar culture-free AST workflow as uRAST.
- Selux Diagnostics: Developer of the Next-Generation Phenotyping (NGP) AST platform aimed at delivering rapid phenotypic AST directly from positive blood cultures. Direct emerging competitor to dRAST in the rapid AST category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
QuantaMatrix social profiles
Digital presenceQuantaMatrix compliance and trust
Trust signalCompliance2 records
QuantaMatrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
QuantaMatrix leadership team
Management profileNumber of profiles
QuantaMatrix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QuantaMatrix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QuantaMatrix
What does QuantaMatrix do?
QuantaMatrix develops and commercializes rapid in-vitro diagnostic systems for clinical microbiology, with flagship applications in bloodstream infection/sepsis antimicrobial susceptibility testing (dRAST), tuberculosis drug susceptibility testing (QDST), Alzheimer's disease screening (QPLEX Alz plus), and cardiovascular diagnostics (Quanti9 and QuantiGal). Its portfolio combines proprietary microfluidic agarose channel hardware, time-lapse imaging software, and multiplex immunoassays, sold as integrated instruments plus consumables to hospital laboratories and reference centers.
Is QuantaMatrix a public or private company?
QuantaMatrix is a public company. It is classified as public and is currently operating.
When was QuantaMatrix founded?
QuantaMatrix was founded in 2010. It employs 101 to 250 people.
Where is QuantaMatrix based?
QuantaMatrix is headquartered in Seoul, South Korea, in the Asia region.
How does QuantaMatrix make money?
Two revenue lines are on record. Diagnostic Systems and Consumables are the primary driver. The others are diagnostic Testing Kits.
Who are QuantaMatrix's main competitors?
Direct peers on record are bioM\u00e9rieux and Accelerate Diagnostics. Broad incumbents are Becton Dickinson (BD), Bruker Corporation, Beckman Coulter (Danaher), Cepheid (Danaher) and Roche Diagnostics. Emerging players are T2 Biosystems, Qvella Corporation and Selux Diagnostics.
Does QuantaMatrix have an API?
No public API is recorded for QuantaMatrix.
What industry is QuantaMatrix in?
QuantaMatrix's product category is In-vitro Diagnostics (Clinical Microbiology). Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 325413 and its SIC code is 2835.